

## Concise report

**Association of anti-citrullinated protein or peptide antibodies with left ventricular structure and function in rheumatoid arthritis****Laura Geraldino-Pardilla<sup>1</sup>, Cesare Russo<sup>1</sup>, Jeremy Sokolove<sup>2,3</sup>, William H. Robinson<sup>2,3</sup>, Afshin Zartoshti<sup>1</sup>, Jenny Van Eyk<sup>4</sup>, Justyna Fert-Bober<sup>4</sup>, Joao Lima<sup>5</sup>, Jon T. Giles<sup>1</sup> and Joan M. Bathon<sup>1</sup>****Abstract**

**Objective.** High levels of ACPAs in RA are associated with more severe arthritis and worse prognosis. However, the role of ACPAs in mediating the increased risk of heart failure in RA remains undefined. We examined whether specific ACPAs were associated with subclinical left ventricular (LV) phenotypes that presage heart failure.

**Methods.** Sera from RA patients without clinical cardiovascular disease were assayed for specific ACPAs using a custom Bio-Plex bead assay, and their cross-sectional associations with cardiac magnetic resonance-derived LV measures were evaluated. High ACPA level was defined as  $\geq$  75th percentile. Findings were assessed in a second independent RA cohort with an expanded panel of ACPAs and LV measures assessed by 3D-echocardiography.

**Results.** In cohort 1 ( $n=76$ ), higher levels of anti-citrullinated fibrinogen<sub>41–60</sub> and anti-citrullinated vimentin antibodies were associated with a 10 and 6% higher adjusted mean LV mass index (LVMI), respectively, compared with lower antibody levels ( $P < 0.05$ ). In contrast, higher levels of anti-citrullinated biglycan<sub>247–266</sub> were associated with a 13% lower adjusted mean LVMI compared with lower levels ( $P < 0.001$ ). In cohort 2 ( $n=74$ ), the association between ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein and LVMI was confirmed: higher anti-citrullinated fibrinogen<sub>556–575</sub> and anti-citrullinated vimentin<sub>58–77</sub> antibody levels were associated with a higher adjusted mean LVMI (19 and 15%, respectively;  $P < 0.05$ ), but no association with biglycan was found.

**Conclusion.** Higher levels of antibodies targeting citrullinated fibrinogen and vimentin peptides or protein were associated with a higher mean LVMI in both RA cohorts, potentially implicating autoimmune targeting of citrullinated proteins in myocardial remodelling in RA.

**Key words:** anti-citrullinated peptide antibody (ACPA), RA, ventricular mass, CVD

**Rheumatology key messages**

- Higher levels of ACPAs targeting citrullinated fibrinogen and citrullinated vimentin peptides or protein were associated with higher left ventricular mass index.
- Seroreactivity towards citrullinated proteins may play a role in myocardial remodelling in RA.

<sup>1</sup>Department of Medicine, Columbia University, College of Physicians & Surgeons, New York, NY, <sup>2</sup>Department of Medicine, Stanford University School of Medicine, Stanford, <sup>3</sup>Department of Medicine, VA Palo Alto Health Care System, Palo Alto, <sup>4</sup>The Heart Institute and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA and <sup>5</sup>Department of Medicine, Johns Hopkins University, Baltimore, MD, USA

Submitted 13 April 2016; revised version accepted 25 October 2016

Correspondence to: Laura Geraldino-Pardilla, Columbia University, College of Physicians & Surgeons, 630 West 168th Street, P&S 10-445, New York, NY 10032, USA. E-mail: lbg2124@columbia.edu

## Introduction

Cardiovascular disease (CVD) represents the leading cause of mortality in RA [1]. RA patients have double the risk for developing heart failure compared with controls [1] even after adjusting for traditional CV risk factors and ischaemic heart disease, suggesting that RA is an independent risk factor for heart failure. Although the excess in myocardial dysfunction in RA remains unexplained, autopsy studies show myocarditis in some patients [2]. Differences in symptoms, myocardial phenotypes, and higher heart failure-related mortality rates in RA vs non-RA patients [3] suggest different mechanisms for myocardial dysfunction in RA vs controls.

ACPAs are a key feature of, and relatively specific for, RA, appearing in the pre-clinical phase of the disease [4]. Whether the citrullinated autoantigens identified from synovium and recognized by RA sera [5–7] are found in the myocardium and contribute to myocardial dysfunction in RA remains unexplored. In RA necropsied myocardia, we reported higher citrullination levels relative to autoimmune and non-autoimmune disease controls, and confirmed myocardial expression of the citrullinating enzyme, peptidyl arginine deiminase [8]. However, the identity of the citrullinated myocardial proteins was not established. Some of the citrullinated autoantigens discovered in RA synovium (vimentin, biglycan, fibronectin) [9] are expressed in their native state in myocardial tissue, raising the possibility that ACPAs against their citrullinated myocardial counterparts may be generated in RA and induce myocardial remodelling.

Using an array of RA-associated autoantigens, we investigated the association of ACPAs with parameters of left ventricular (LV) structure and function in two RA cohorts without clinical CVD. We hypothesized that patients with high ACPA levels would have different myocardial phenotypes from patients with lower antibody levels.

## Methods

### Patients

Cohort 1 included 76 patients in the Evaluation of Subclinical Cardiovascular disease and Predictors of Events in RA (ESCAPE-RA) study, randomly selected to undergo cardiac MRI [10] in addition to cardiovascular phenotyping. Participants were 45–84 years old, met 1987 ACR RA criteria [11], had RA for  $\geq 6$  months, and had no clinical CVD (defined as coronary artery disease, myocardial infarction, heart failure, stroke). Cohort 2 included the first 74 enrollees in Rheumatoid arthritis study of The Myocardium (RHYTHM), an ongoing study of subclinical myocardial phenotypes in RA patients without CVD in which all participants underwent 3D-echocardiography. RHYTHM inclusion/exclusion criteria were identical to ESCAPE-RA except for an age  $\geq 18$  years. Studies were approved by the Johns Hopkins Medical Institutions (ESCAPE-RA) and Columbia University (RHYTHM) Institutional Review Boards, which included

approval for this study. Informed consent was obtained for both the ESCAPE-RA and RHYTHM studies.

### Outcome measures

#### Cardiac MRI

Cardiac MRI (CMR) in ESCAPE-RA was performed using a 1.5-T magnet CV/i (GE Healthcare, Piscataway, NJ, USA). Ejection fraction, stroke volume and body surface area (BSA)-indexed end-diastolic and end-systolic volumes, and left ventricular mass (LVM) were analysed as previously described [10].

#### 3D echocardiography

RHYTHM participants underwent transthoracic 3D-echocardiography using the Philips iE 33 system. 3D-LV volumes and mass were measured using the Philips QLAB Advanced Quantification software 8.1; LV end-diastolic and end-systolic volumes were indexed by BSA. LVM was calculated as the difference between the epicardial and endocardial volumes multiplied by the specific myocardial tissue mass and indexed by BSA. The LV mass-to-end-diastolic volume (M/V) ratio was used as a parameter of LV geometry.

### Laboratory assays

Phlebotomy was performed at the same visit as the CMR or 3D-echocardiography. Serum and plasma were centrifuged and stored at  $-70^{\circ}\text{C}$ .

#### Anti-CCP assays

Anti-CCP-antibodies were assessed by ELISA (CCP2 kit, for ESCAPE-RA, and CCP3 kit for RHYTHM; Inova Diagnostics, Woburn, MA, USA), with positivity defined as  $\geq 60$  U.

#### ACPA assays

A multiplex platform, utilizing a custom Bio-Plex bead-based autoantibody assay, was used for the analysis of autoantibodies targeting specific RA-associated citrullinated and native (non-citrullinated) protein or peptides, as previously described [5]. A high ACPA level was defined as  $\geq 75$ th percentile. For ESCAPE-RA, the array consisted of 17 citrullinated and three native proteins or peptides [6]. For RHYTHM, 30 citrullinated and five native proteins or peptides were measured [7]. Intra-assay and interassay coefficients of variance ranged from 0.4 to 5.5% and 0.9 to 10%, respectively.

#### Additional assays

High-sensitivity CRP, IL-6 and lipid levels were measured as previously described [10, 12]. RF was assessed by ELISA, with positivity defined as  $\geq 40$  U.

### Clinical covariates

Demographics, smoking and CVD family history were collected from identical questionnaires for both cohorts. Hypertension, diabetes, BMI, BSA, medication use and RA disease duration and activity were ascertained as previously described [10, 12].

## Statistical methods

Summary statistics were examined; comparisons were made using Student's *t* test and Wilcoxon's rank-sum test for normally and non-normally distributed continuous variables, respectively. Counts and percentages were calculated for categorical variables, compared using the chi-square or Fisher's exact test. Multivariable linear regression was used to model the association of LV structure and function measures with the panel of seroreactivities towards citrullinated and non-citrullinated autoantigens. Tolerance was calculated to avoid comodelling collinear variables. Confounders were defined as variables associated with both the outcome (cardiac structure and function measures) and predictors (ACPA levels). Statistical calculations were performed using SAS 9.4 (SAS Institute, Cary, NC, USA). A two-tailed  $\alpha$  of 0.05 was defined as the level of statistical significance.

## Results

### Patient characteristics

Patient characteristics are summarized in Table 1. In ESCAPE-RA, the mean age was 59 years with 51% females and 85% self-identified as white. RHYTHM participants had a mean age of 54 years, 85% females and 36% whites. In both studies, the median disease duration was 7 years, two-thirds were anti-CCP antibody positive and mean RA disease activity was moderate. Hypertension and diabetes were more frequent in RHYTHM patients.

With anti-CCP-antibody level dichotomized at the 75th percentile, in ESCAPE-RA a lower BMI and higher percentage of smokers were noted in the high anti-CCP group. In RHYTHM, more patients with RF  $\geq 40$  U and a trend towards higher prednisone use were observed in the high anti-CCP group. ESCAPE-RA patients in the high anti-CCP group had a lower stroke volume and a lower mean LVMI, as previously published, although not reaching statistical significance in this analysis (due to analysing anti-CCP as a categorical rather than continuous variable). In RHYTHM, LVMI was not different between anti-CCP groups, although a trend towards a higher LVMI in the high anti-CCP-antibody group was seen. Given this discrepancy, specific ACPAs were examined.

### Association of ACPAs with LV parameters

The citrullinated and non-citrullinated proteins or peptides that comprised the autoantigen microarrays are listed in Table 2.

#### ESCAPE-RA

Higher anti-citrullinated (cit) fibrinogen<sub>41-60</sub> and anti-cit-vimentin antibody levels were associated with a higher mean LVMI compared with lower antibody levels. In contrast, high anti-cit-biglycan<sub>247-266</sub> antibody levels were associated with a lower mean LVMI compared with lower antibody levels. After adjusting for confounders, these associations remained significant.

#### RHYTHM

Higher anti-cit-fibrinogen<sub>556-575</sub>, anti-cit-vimentin<sub>58-77</sub> and anti-cit-fibronectin<sub>1029-1042</sub> antibody levels were associated with a higher mean LVMI compared with lower antibody levels in unadjusted and adjusted analyses. Higher anti-citrullinated biglycan<sub>247-266</sub> levels were not associated with LVMI in this cohort.

In both cohorts, LV M/V ratios were normal (suggesting an eccentric LV geometry) with no differences noted per anti-CCP or ACPA strata ( $P > 0.05$ ). Other measured cardiac parameters were not associated with specific ACPA reactivities in either cohort (data not shown). No association was seen between LVMI and levels of seroreactivity to the non-citrullinated protein controls in either cohort.

## Discussion

This is the first investigation of the association of specific ACPAs with LV structure, function and geometric parameters in RA patients. We found in two independent RA cohorts, despite different demographics and imaging methodologies, that high levels of ACPAs targeting cit-vimentin and cit-fibrinogen protein or peptides were associated with higher mean LVMI. While only evaluated in the RHYTHM participants, a similar association was found for ACPAs targeting cit-fibronectin peptides. The specificity of these responses was confirmed by lack of association of LVMI with antibody levels against non-citrullinated homologue proteins.

Increased LVM is the most common form of adverse LV remodelling, considered a subclinical phenotype in the pathway to heart failure development [13]. In the Framingham Study, for every 50 g increase in LVM, CVD increased by 1.49- and 1.57-fold for men and women, respectively, with higher relative risks for cardiovascular death of 1.73 and 2.12, respectively [14]. In our studies, although the higher LVMI noted in the RA patients with high-ACPA levels fell within the normal range, a progressive increase in LVM is a heart failure precursor in the general population, and strong sudden cardiac death predictor, even in subsets with normal ejection fraction [13, 14]. A recent meta-analysis of cross-sectional studies in RA patients without clinical heart failure revealed no consensus on LVMI differences between RA and controls, as higher LVMI, lower LVMI and no difference in LVMI have all been reported [10, 15]. This could be due to variability in time of assessment along the continuum of the RA disease process. Unfortunately, longitudinal measurements of LVMI in RA patients transitioning from pre-clinical to clinical heart failure are lacking.

Correlation of specific ACPAs with myocardial phenotypes in RA may deepen the understanding of disease pathogenesis through identification of potentially relevant autoantigens in LV impairment. Commercially available anti-CCP assays result in mass-averaging of the ACPA response and do not provide information about the autoantibody response sub-specificities. Indeed, our studies using two different commercial anti-CCP assays showed no consistent relationship between anti-CCP titres and

TABLE 1 Patient characteristics according to cohort and anti-CCP status

	ESCAPE			RHYTHM			
	Total (n = 76)	Lower CCP Ab (n = 57)	Higher CCP Ab (n = 19)	Total (n = 74)	Lower CCP Ab (n = 55)	Higher CCP Ab (n = 19)	P-value
Age, mean (s.d.), years	59 (9)	59 (9)	61 (9)	54 (13)	53 (13)	56 (14)	0.52
Female, n (%)	39 (51)	29 (51)	10 (53)	63 (85)	49 (89)	14 (74)	0.10
Non-Hispanic white, n (%)	65 (85)	49 (86)	16 (84)	27 (36)	22 (40)	5 (26)	0.29
RA duration, median (range), years	7 (3-17)	7 (4-16)	11 (5-19)	7 (3-17)	8 (3-14)	7 (1-15)	0.46
DAS28-CRP, median (IQR), units	3.3 (2.7-4.7)	3.2 (2.7-4.1)	3.7 (2.8-4.3)	3.9 (2.9-4.5)	3.9 (3.0-4.4)	4.5 (2.6-4.8)	0.60
Anti-CCP positivity, n (%)	54 (71)	35 (61)	19 (100)	47 (67)	30 (57)	19 (100)	0.00
RF positivity, n (%)	51 (67)	36 (63)	15 (79)	39 (56)	25 (47)	14 (82)	0.01
HAC, median (IQR), units	0.7 (0.1-1.3)	0.87 (0.1-1.3)	0.25 (0-1.25)	1 (0.5-1.75)	0.9 (0.4-1.5)	1.2 (1-1.8)	0.13
IL-6, median (IQR), ng/ml	2.5 (1.5-6.1)	2.3 (1.2-5.8)	3.0 (1.9-10)	2.7 (1.5-8.7)	2.4 (1.3-7.9)	4.5 (2.2-15)	0.14
C-RP, median (IQR), mg/l	2.0 (1-4.6)	1.9 (0.9-3.8)	3.5 (1-9.6)	2.7 (0.6-6.5)	2.2 (0.6-6.6)	2.8 (1.2-6.3)	0.72
Current non-biologic use, n (%)	67 (88)	51 (89)	16 (84)	51 (73)	38 (72)	13 (76)	0.70
Current biologic use, n (%)	37 (49)	26 (46)	11 (58)	23 (33)	17 (32)	6 (35)	0.81
Current prednisone use, n (%)	30 (39)	23 (40)	7 (37)	24 (34)	15 (28)	9 (53)	0.06
Current prednisone dose, median (IQR), mg/day	2.4 (0-5)	0 (0-5)	0 (0-5)	5 (4-10)	5 (2-10)	7.5 (5-10)	0.37
Diabetes, n (%)	5 (7)	5 (9)	0 (0)	8 (11)	6 (11)	2 (12)	0.99
Hypertension, n (%)	27 (35)	21 (37)	6 (32)	30 (40)	22 (40)	8 (42)	0.87
SBP, mean (s.d.), mmHg	129 (17)	128 (16)	133 (20)	117 (19)	118 (20)	117 (15)	0.86
DBP, mean (s.d.), mmHg	77 (9)	76 (9)	79 (9)	70 (10)	70 (11)	71 (8)	0.50
Antihypertensive agents, n (%)	27 (35)	21 (37)	6 (32)	27 (36)	19 (34)	8 (42)	0.55
Total cholesterol, mean (s.d.), mmol/l	5.0 (1.1)	5.1 (1.1)	4.9 (1.1)	4.9 (1.0)	4.9 (1.1)	5.0 (0.7)	0.88
LDL-C, mean (s.d.), mmol/l	3.0 (0.8)	3.0 (0.9)	3.0 (0.7)	2.8 (0.9)	2.7 (0.9)	2.9 (0.7)	0.43
HDL-C, mean (s.d.), mmol/l	1.4 (0.5)	1.4 (0.5)	1.4 (0.5)	1.6 (0.5)	1.6 (0.5)	1.4 (0.5)	0.24
Triglycerides, mean (s.d.), mmol/l	1.3 (0.7)	1.3 (0.7)	1.1 (0.6)	1.3 (0.7)	1.3 (0.7)	1.3 (0.8)	0.37
Lipid lowering agents, n (%)	12 (16)	7 (12)	5 (26)	12 (16)	9 (16)	3 (16)	1.0
Current smoking, n (%)	12 (16)	6 (10)	6 (32)	5 (7)	3 (6)	2 (12)	0.59
Ever smoking, n (%)	48 (63)	35 (61)	13 (68)	30 (43)	22 (41)	8 (47)	0.69
BMI, kg/m <sup>2</sup>	27 (5)	28 (5)	25 (4)	28 (6)	28 (6)	29 (7)	0.45
CAC score, median (IQR)	6 (0-215)	5.7 (0-227)	8.6 (0-213)	0 (0-45)	0 (0-67)	0 (0-45)	0.84
LV mass, mean (s.d.), g	120 (26)	123 (27)	113 (22)	103 (34)	98 (34)	117 (34)	0.05
LVMI, mean (s.d.), g/BSA	63 (10)	64 (10)	61 (9)	60 (16)	59 (17)	66 (14)	0.12
End-diastolic volume index, mean (s.d.), ml/BSA	64 (12)	66 (12)	60 (8)	52 (17)	50 (17)	57 (18)	0.16
End-systolic volume index, mean (s.d.), ml/BSA	21 (6)	22 (6)	21 (5)	22 (8)	21 (6)	25 (14)	0.20
LV M/V ratio, median (IQR), g/ml	1 (0.9-1.1)	1 (1-1.1)	1 (1-1.1)	1.1 (0.9-1.4)	1.3 (0.9-1.7)	1.2 (0.5-1.8)	0.73
Stroke volume, mean (s.d.), ml	80 (19)	82 (20)	72 (15)	57 (18)	55 (16)	61 (24)	0.35
Ejection fraction, mean (s.d.), %	67 (6)	67 (6)	65 (7)	60 (15)	62 (14)	55 (19)	0.09

BSA: body surface area; CAC: coronary artery calcium; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LV: left ventricle; LVMI: left ventricular mass index; M/V: mass-to-volume; SBP: systolic blood pressure.

**TABLE 2** Left ventricular mass index (g/m<sup>2</sup>) per autoreactivity level in the ESCAPE-RA and RHYTHM cohorts

	ESCAPE-RA (n = 76)				RHYTHM (n = 74)			
	Univariable model		Multivariable model <sup>a</sup>		Univariable model		Multivariable model <sup>b</sup>	
	Lower level	Higher level	Lower level	Higher level	Lower level	Higher level	Lower level	Higher level
Autoantigen								
Fibrinogen cit	63 (60, 65)	64 (59, 68)			59 (54, 64)	64 (57, 72)		
Fibrinogen A 41–60 cit	58 (54, 63)	68 (63, 73)**	61 (57, 64)	67 (63, 71)*	59 (55, 64)	64 (56, 71)	58 (53, 62)	69 (61, 77)**
Fibrinogen A 556–575 cit	62 (60, 65)	65 (61, 70)			58 (53, 62)	68 (61, 76)**		
Fibrinogen A 211–230 cit	63 (60, 66)	63 (59, 68)			60 (55, 64)	63 (55, 70)		
Fibrinogen A 616–635 cit	63 (60, 66)	63 (59, 68)			58 (54, 63)	66 (59, 74)		
Fibrinogen A 582–599 cit <sup>c</sup>	—	—			59 (54, 63)	65 (57, 72)		
Fibrinogen A 27–43 cit <sup>c</sup>	—	—			59 (54, 63)	65 (57, 72)		
Fibrinogen B 36–52 cit <sup>c</sup>	—	—			59 (55, 64)	64 (56, 72)		
Fibrinogen B 54–72 cit <sup>c</sup>	—	—			60 (55, 64)	62 (54, 70)		
Fibrinogen B 246–267 cit <sup>c</sup>	—	—			60 (55, 64)	62 (55, 70)		
Vimentin cit	58 (55, 61)	68 (64, 73)**	62 (59, 64)	66 (62, 70)*	59 (55, 64)	63 (56, 71)	58 (54, 63)	67 (60, 75)*
Vimentin 58–77 cit	63 (61, 66)	62 (57, 66)			58 (54, 63)	67 (59, 74)*		
Vimentin 1–16 cit <sup>c</sup>	—	—			60 (55, 64)	62 (55, 70)		
Apolipoprotein A1 cit	64 (61, 66)	61 (57, 66)			59 (55, 64)	64 (56, 71)		
Apolipoprotein A1 231–248 cit <sup>c</sup>	—	—			59 (54, 64)	64 (57, 71)		
Apolipoprotein E cit	63 (61, 66)	62 (57, 67)			59 (55, 64)	64 (56, 71)		
Apolipoprotein E 277–296 cit	63 (60, 65)	64 (59, 68)			58 (54, 63)	66 (59, 73)		
Filaggrin 48–65 cit	63 (60, 65)	65 (60, 69)			59 (55, 63)	64 (57–72)		
Filaggrin 48–65 cyclic cit <sup>c</sup>	—	—			58 (54, 63)	65 (58, 72)		
Biglycan 247–266 cit	67 (63, 71)	59 (55, 64)*	68 (64, 71)	60 (56, 64)**	58 (54, 63)	66 (60, 73)		
Histone 2A cit <sup>c</sup>	—	—			59 (55, 64)	64 (56, 71)		
Histone 2A 1–20 cit	63 (61, 66)	62 (57, 66)			59 (55, 74)	64 (56, 72)		
Histone 2A 1–20 cit sm <sup>c</sup>	—	—			59 (54, 63)	65 (57, 73)		
Histone 2B cit	63 (61, 66)	62 (58, 70)			59 (54, 63)	66 (58, 73)		
Histone 2B62–81 cit	63 (61, 66)	62 (58, 67)			61 (56, 65)	59 (52, 67)		
Clusterin 231–250 cit	63 (60, 65)	64 (59, 68)			59 (54, 63)	65 (57, 72)		
Clusterin 221–240 cit <sup>c</sup>	—	—			60 (55, 64)	62 (55, 70)		
Enolase cit <sup>c</sup>	63 (61, 66)	63 (58, 67)			—	—		
Enolase A 5–21 cit <sup>c</sup>	—	—			60 (55, 64)	62 (55, 70)		
Fibronectin cit <sup>c</sup>	—	—			59 (55, 64)	64 (57, 72)		
Fibronectin 1029–1042 cit <sup>c</sup>	—	—			57 (53, 62)	69 (62, 77)**	57 (52, 61)	72 (64, 79)**

(continued)

TABLE 2 Continued

	ESCAPE-RA (n = 76)				RHYTHM (n = 74)			
	Univariable model		Multivariable model <sup>a</sup>		Univariable model		Multivariable model <sup>b</sup>	
	Lower level	Higher level	Lower level	Higher level	Lower level	Higher level	Lower level	Higher level
Non-citrullinated controls								
Fibrinogen	62 (60, 65)	65 (61, 70)			58 (54, 63)	66 (58, 73)		
Apo A1	62 (60, 65)	66 (61, 70)			60 (56, 65)	62 (54, 69)		
Apo E <sup>d</sup>	63 (60, 65)	65 (60, 69)			—	—		
Vimentin <sup>c</sup>	—	—			59 (55, 64)	64 (56, 72)		
Histone 2A <sup>c</sup>	—	—			58 (54, 63)	64 (58, 71)		
Histone 2B <sup>c</sup>	—	—			61 (56, 66)	60 (53, 68)		

Mean LVMI (g/m<sup>2</sup>) and 95% CI of low vs high autoreactivities (dichotomized at the 75th percentile). <sup>a</sup>Adjusted for gender, smoking, hypertension and LDL-cholesterol. <sup>b</sup>Adjusted for diastolic blood pressure. <sup>c</sup>Only tested in the RHYTHM cohort. <sup>d</sup>Only tested in the ESCAPE-RA cohort. cit, citrullinated ; sm= small peptide. P < 0.05, \*\*P < 0.01.

LVMI across the two cohorts, in contrast to the consistency observed in the association of high levels of ACPAs targeting cit-fibrinogen and cit-vimentin peptides or protein and the LVMI. Importantly, all autoantigens identified here are known myocardial constituents and/or are associated with a risk for sudden cardiac death [16–18]. It is therefore possible that citrullination of these proteins might occur in RA hearts and serve as targets for RA-associated ACPAs leading to tissue damage.

Whether citrullination plays a role in myocardial disease in general, or in RA myocardial disease in particular, is a topic of interest. Citrullination is a ubiquitous finding in inflamed tissues [8]. Indeed, although higher in RA hearts, we previously reported citrullination in necropsied hearts of patients with other autoimmune diseases and non-autoimmune myocarditis as well [8]. Recently, in myocardial tissues from non-RA patients with heart failure, we identified a myocardial citrullinated proteome that included citrullinated vimentin and key myofilament structural proteins including citrullinated myosin and tropomyosin [19]. Citrullination of vimentin, a mesenchymal cell intermediate filament component, results in collapse of the filament network, while citrullination of myosin and tropomyosin alters their assembly and contractility patterns [19]. However, the consequences of ACPAs against putative citrullinated myocardial proteins are not known. Given the specificity of ACPA generation as a feature of RA, it is tempting to speculate that these autoantibodies contribute to the excess risk of heart failure in RA vs non-RA controls.

Although a concentric geometry (increased LV M/V ratio) has been previously described in RA-associated increased LVM, in our study the LVM increase in high-level ACPA groups was associated with eccentric geometry (normal LV M/V ratio), which is commonly seen in primary myocardial injury. It is possible that the increase in LVM associated with higher ACPA levels reflects ACPA-mediated myocardial injury but this remains unknown.

Strengths of our study include the consistency of the association of ACPAs targeting the same protein or peptides within the protein with the same myocardial phenotype across two RA cohorts despite ethnic differences and two different but well validated and sensitive methods for LV structure and function measuring, adding to the robustness of the findings. Additional strengths include extensive cardiovascular and RA characteristic phenotyping, and nearly identical inclusion/exclusion criteria of the two cohorts; and the utilization of a broad array of antigens, both citrullinated and native, with potential relevance to myocardial disease.

Limitations of our study include its cross-sectional nature and testing of multiple comparisons that precludes establishment of causation. Also, LVMI was measured by different techniques in the two cohorts; however, a high correlation between these modalities has been established [20]. Finally, the RA microarrays utilized here include a set of synovium-identified autoantigens; thus, potential additional autoantigens of greater myocardial relevance were possibly missed. However, current studies

are in progress to identify citrullinated myocardial proteins recognized by RA sera.

In conclusion, higher levels of ACPAs targeting citrullinated vimentin and fibrinogen protein or peptides were associated with a higher LVMI compared with lower antibody levels in two RA cohorts without clinical CVD. This association suggests a pathophysiological link between autoimmunity and myocardial remodelling.

## Acknowledgements

The authors thank the patients of the ESCAPE-RA and RHYTHM cohorts for their participation in these studies and the Clinical and Translational Science Award grant UL1 TR000040 of the National Institutes of Health.

**Funding:** Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases under Award Number AR-050026 and AR050026-08S1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health the Clinical and Translational Science Award grant UL1 TR000040 of the National Institutes of Health.

**Disclosure statement:** J.B has received consultancy fees from Regeneron. All other authors have declared no conflicts of interest.

## References

- 1 Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. *J Rheumatol* 2003;30:36–40.
- 2 Lebowitz WB. Heart in rheumatoid arthritis (rheumatoid disease) – a clinical and pathological study of 62 cases. *Ann Intern Med* 1963;58:102.
- 3 Nicola PJ, Maradit-Kremers H, Roger VL *et al.* The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. *Arthritis Rheum* 2005;52:412–20.
- 4 Sokolove J, Bromberg R, Deane KD *et al.* Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. *PLoS One* 2012;7:e35296.
- 5 Wolfgang H, Tomooka BH, Batiwalla F *et al.* Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. *Arthritis Res Ther* 2009;11:R76.
- 6 Solow EB, Yu F, Thiele GM *et al.* Vascular calcifications on hand radiographs in rheumatoid arthritis and associations with autoantibodies, cardiovascular risk factors and mortality. *Rheumatology* 2015;54:1587–95.
- 7 Sokolove J, Johnson DS, Lahey LJ *et al.* Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. *Arthritis Rheumatol* 2014;66:813–21.
- 8 Giles JT, Fert-Bober J, Park JK *et al.* Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. *Arthritis Res Ther* 2012;14:R39.
- 9 Fert-Bober J, Sokolove J. Proteomics of citrullination in cardiovascular disease. *Proteomics Clin Appl* 2014;8:522–33.
- 10 Giles JT, Malayeri AA, Fernandes V *et al.* Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. *Arthritis Rheum* 2010;62:940–51.
- 11 Arnett FC, Edworthy SM, Bloch DA *et al.* The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:15–324.
- 12 Winchester R, Giles JT, Nativ S *et al.* Association of elevations of specific T cell and monocyte subpopulations in rheumatoid arthritis with subclinical coronary artery atherosclerosis. *Arthritis Rheumatol* 2016;68:92–102.
- 13 Cheng S, Vasan RS. Advances in the epidemiology of heart failure and left ventricular remodeling. *Circulation* 2011;124:e516–9.
- 14 Stevens SM, Reinier K, Chugh SS. Increased left ventricular mass as a predictor of sudden cardiac death. Is it time to put it to the test? *Circulation Arrhythmia Electrophysiol* 2013;6:212–7.
- 15 Aslam F, Bandiali SJ, Khan NA, Alam M. Diastolic dysfunction in rheumatoid arthritis: a meta-analysis and systematic review. *Arthritis Care Res* 2013;65:534–43.
- 16 Kunutsor SK, Kurl S, Zaccardi F, Laukkanen JA. Baseline and long-term fibrinogen levels and risk of sudden cardiac death: A new prospective study and meta-analysis. *Atherosclerosis* 2015;245:171–80.
- 17 Mahesh B, Leong HS, McCormack A *et al.* Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. *Am J Pathol* 2007;170:1415–27.
- 18 Zhang Y, Zhou X, Krepinsky JC *et al.* Association study between fibronectin and coronary heart disease. *Clin Chem Lab Med* 2006;44:37–42.
- 19 Fert-Bober J, Giles JT, Holewinski RJ *et al.* Citrullination of myofilament proteins in heart failure. *Cardiovasc Res* 2015;108:232.
- 20 Avegliano GP, Costabel JP, Asch FM *et al.* Utility of real time 3D echocardiography for the assessment of left ventricular mass in patients with hypertrophic cardiomyopathy: comparison with cardiac magnetic resonance. *Echocardiography* 2015;33:431–6.